about
The potential use of biomarkers in predicting contrast-induced acute kidney injuryBowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review.Home infusion program with enzyme replacement therapy for Fabry disease: The experience of a large Italian collaborative groupAcute kidney injury by radiographic contrast media: pathogenesis and prevention.Measuring and estimating GFR and treatment effect in ADPKD patients: results and implications of a longitudinal cohort study.A classical phenotype of Anderson-Fabry disease in a female patient with intronic mutations of the GLA gene: a case reportEffect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial.Nephrotic syndrome and autosomal dominant polycystic kidney disease.Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute StudyLate diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease.Role of reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy.Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome.Molecular mechanisms of renal cellular nephrotoxicity due to radiocontrast mediaNutritional treatment in chronic kidney disease: the concept of nephroprotection.What indication, morbidity and mortality for central pancreatectomy in oncological surgery? A systematic review.Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study.Reversal of radiocontrast medium toxicity in human renal proximal tubular cells by white grape juice extract.Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature.The ischemic/nephrotoxic acute kidney injury and the use of renal biomarkers in clinical practice.Fanconi syndrome with lysinuric protein intolerance.Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin.Mycophenolic acid inhibits the phosphorylation of NF-kappaB and JNKs and causes a decrease in IL-8 release in H2O2-treated human renal proximal tubular cells.Long-term Effects of Octreotide on Liver Volume in Patients With Polycystic Kidney and Liver Disease.Effect of a Short-Course Treatment with Synbiotics on Plasma p-Cresol Concentration in Kidney Transplant Recipients.Early markers of Fabry disease revealed by proteomics.Efficacy of a reduced pill burden on therapeutic adherence to calcineurin inhibitors in renal transplant recipients: an observational study.Genetic variants associated with gastrointestinal symptoms in Fabry disease.A strange epigastric pain.Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter?EC-MPS permits lower gastrointestinal symptom burden despite higher MPA exposure in patients with severe MMF-related gastrointestinal side-effects.Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy.Endocrine dysfunction in patients with Fabry disease.Arterial aneurysms: autosomal dominant polycystic kidney disease, Marfan syndrome or both?Atorvastatin improves the course of ischemic acute renal failure in aging rats.Synergy between the pharmacological chaperone 1-deoxygalactonojirimycin and agalsidase alpha in cultured fibroblasts from patients with Fabry disease.Prevalence of hepatitis C virus infection in different population groups in southern Italy.Quercetin protects against radiocontrast medium toxicity in human renal proximal tubular cells.Metabolic effects of two low protein diets in chronic kidney disease stage 4-5--a randomized controlled trial.Genetic variants associated with Fabry disease progression despite enzyme replacement therapy.Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial.
P50
Q28078393-A04EC2AB-C1A6-454F-B9AE-9121C6EFA849Q30241402-4190BC1B-3BC2-4CEF-8E63-C9BA27A6B6F9Q33835524-7DDE734D-9E84-4A1E-8FD0-5AC03FD1672EQ34114127-DECCCA03-029C-4661-A42F-AD3BA7407D95Q34185922-1B936AC5-62AE-43AB-B40A-02BC8EB24C4FQ34298121-718792F8-7E52-4EA1-A53F-AB887922538CQ35188367-12D84B7F-1FC3-47BC-ABA2-C4F607048EFFQ35453142-A1BCBF22-5CCB-4F86-988A-D93F01BFE0F0Q35818080-46ADF848-39ED-4E75-B6ED-CF15813B987BQ35851331-EB148A14-DD11-4ABA-8F57-6E21CF78E62FQ37477897-1ECA8307-E6A6-4EAD-8A3A-F391D051EB72Q37670299-550B90C6-2831-487D-A1C9-6233D17B0C80Q38205449-0BAE531B-2E54-4A88-8015-E4E6497FBAB7Q38260544-E0B5BCA7-1418-450B-A3BE-9376382FE14EQ38680812-5A6047DE-BDB3-4365-8D0A-6D0391C80DA7Q38839433-84E4FDC4-EA12-4A29-B4AF-7A6B6F304F4BQ38918390-2BF939AD-8C21-428A-A0A2-50BB0EA60721Q38949519-E363C799-353F-4A61-8816-87FCD4151F38Q39051952-42E4F8F2-2080-4C63-81EE-D94E018440F7Q39368798-E70D65C3-B039-4BA5-84E0-E22351111804Q39446900-4F627268-C3B5-43BF-A85C-F681AF0D4C0AQ39725678-3373E4B4-27B5-48E9-9C04-362ABAE3DD8CQ40024537-F0E1C23A-7E80-4B9D-B319-42DBE0B3A34FQ40051571-4A8B52DA-4EC5-4400-B6F9-E0024491AD26Q41457854-3AA7F43E-B3D4-46E1-82EC-6DC5687DF6C3Q41871356-35F709B1-F436-45C1-B7CF-59135EA4E3B1Q42316513-32F285FB-3312-452A-B52F-1501DD3A0ED3Q42668329-711E4D14-2647-41B4-9C6D-21FBA71F8F08Q43097259-4C9DA4E0-8F66-4389-AB2E-A609F523D838Q43298296-49DE80D3-042C-4461-92BE-65F9434F242CQ43657220-45489A75-47FE-4DDD-88D0-5F48EBBA7463Q43776388-B3588B7F-0F12-4D67-A7EA-DC77FC090743Q43933427-D01B2FB0-9409-41E6-AC4F-22DF0D2DE046Q44807513-8F421DC2-0119-4C9C-BCDD-B6122DCFFBE9Q45293710-09893B26-E57E-4F79-93B4-BE13015D3445Q45503085-8FF894B6-B809-4152-A9F7-D90ED603F3E7Q46281757-43BC010A-D563-494A-B8BC-95D17F867171Q46915252-7DD3DE4A-F43B-4482-8830-79122D72F298Q47094778-A7A5474F-AA05-4716-B96A-D20B5E7C32FBQ47715661-680F110E-498F-4976-86A3-567FCA711808
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Pisani
@ast
Antonio Pisani
@en
Antonio Pisani
@es
Antonio Pisani
@nl
type
label
Antonio Pisani
@ast
Antonio Pisani
@en
Antonio Pisani
@es
Antonio Pisani
@nl
prefLabel
Antonio Pisani
@ast
Antonio Pisani
@en
Antonio Pisani
@es
Antonio Pisani
@nl
P106
P1153
7006447950
P21
P31
P496
0000-0003-0241-8323